Top news of the week: 04.08.2020.

#COVID19 #biospace #pandemic #COVID #treatment #biotechnology #vaccine #coronavirus #pharmaceuticals #lifesciences

Career And Jobs

On Jul 30, 2020
@GENbio shared
#Massachusetts #Biopharma Industry Weathers #COVID19 Impacts on Jobs, Financing: https://t.co/KsdqKw6x62 https://t.co/0FvDGNL3js
Open

Massachusetts Biopharma Industry Weathers COVID-19 Impacts on Jobs, Financing

Massachusetts Biopharma Industry Weathers COVID-19 Impacts on Jobs, Financing

Massachusetts’ top-tier biopharma cluster is weathering the storm wreaked by COVID-19 after a year in which it continued to attract jobs, especially R&D jobs,and venture capital (VC) ...

On Jul 31, 2020
@biospace shared
Biopharma Update on the Novel Coronavirus: July 31 #biospace #lifesciences #biotechnology #pharmaceuticals #COVID-19 #coronavirus #pandemic #COVID19 #treatment #vaccine https://t.co/Zd8hx3RMCD
Open

Biopharma Update on the Novel Coronavirus: July 31

Biopharma Update on the Novel Coronavirus: July 31

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 31, 2020.

On Aug 3, 2020
@biospace shared
Biopharma Update on the Novel Coronavirus: August 3 #biospace #lifesciences #biotechnology #pharmaceuticals #COVID-19 #coronavirus #pandemic #COVID19 #treatment #vaccine https://t.co/eZa4s4KMfo
Open

Biopharma Update on the Novel Coronavirus: August 3

Biopharma Update on the Novel Coronavirus: August 3

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 3, 2020.

On Jul 29, 2020
@MassBio shared
“In 2019, we saw some of the most severe legislation around drug pricing for the industry, both in Massachusetts and federally, which led to a decline in investment as we predicted it would,” @BobCoughlin on our Industry Snapshot, as reported by @endpts https://t.co/6XuAU8RQvH
Open

After down year, 2020 brings new cash into Massachusetts biotech

After down year, 2020 brings new cash into Massachusetts biotech

The sea of cash that has hit biotech since the pandemic began has not left out its biggest sector: Massachusetts. Through the first half of 2020, venture capital firms have poured more than ...

On Jul 28, 2020
@Proclinical shared
Looking for a new role? We are looking for experts from around the world to fill our wide range of exciting medical affairs roles. Visit our page to learn more and apply now. https://t.co/m0PhuN31zI #GlobalGrowthPartners #Staffing #CareerOpportunities #MedicalAffairs
Open

Medical Affairs jobs

Medical Affairs jobs

Medical affairs recruitment. Vacancies including medical advisor, medical director & manager roles. Apply online.

On Jul 29, 2020
@FierceBiotech shared
Rather than switching genes on and off, cutting out disease-causing genes or replacing them with healthy versions, Omega’s platform is designed to adjust gene expression to healthy levels https://t.co/7A0kTRqRGu
Open

'Genome-tuning' biotech Omega Therapeutics snags $85M as it aims for the clinic

'Genome-tuning' biotech Omega Therapeutics snags $85M as it aims for the clinic

Omega Therapeutics' $85 million cash boost will push a pipeline of treatments toward the clinic as well as bankroll the identification of new targets for genomic medicines. Rather than ...

On Aug 3, 2020
@JohnCendpts shared
RT @AmberTongPW: CAR-T filing in sight, Frank Zhang grabs full control of J&J-partnered Legend Biotech, steps down from GenScript - https://t.co/eHeHoatFIb
Open

CAR-T filing in sight, Frank Zhang grabs full control of J&J-partnered Legend Biotech, steps down from GenScript

CAR-T filing in sight, Frank Zhang grabs full control of J&J-partnered Legend Biotech, steps down from GenScript

Two months after Yuan Xu steered Legend Biotech to a $424 million public debut on the Nasdaq, founder and chairman Frank Zhang is grabbing the reins as CEO. In conjunction with the move, ...

On Jul 29, 2020
@JohnCendpts shared
Roche declares a PhIII failure for Covid-19 as the IL-6 repurposing theory bites the dust https://t.co/GVEZXh3b2e
Open

Roche declares a PhIII failure for Covid-19 as the IL-6 repurposing theory bites the dust

Roche declares a PhIII failure for Covid-19 as the IL-6 repurposing theory bites the dust

Another big IL-6 drug has failed to move the needle for Covid-19 patients, leaving that particular field of repurposed drug R&D on the ropes for the pandemic. This morning it was Roche’s ...